Amarin Corporation Earnings Call Transcripts
Fiscal Year 2026
-
Q3 delivered the first profit in two years, with $9M operating cash flow and $324M cash and investments, while revenue fell on U.S. pricing pressure. International demand grew strongly, and EMT2 showed an overall-survival benefit despite missing its primary endpoint.
-
Q2 2026 saw strong international growth for VASCEPA, especially in Europe via the Recordati partnership, and stable U.S. performance despite pricing pressure. Operating loss narrowed, cash flow remained positive, and restructuring drove significant cost savings.
-
Q2 2024 revenue declined year-over-year due to U.S. generic competition, but international growth, especially in Europe and China, offset some pressure. Cost-saving initiatives improved profitability, and the company remains focused on global expansion and maintaining U.S. market leadership.
-
Q1 2026 saw revenue growth, improved margins, and a second consecutive quarter of positive cash flow, driven by a new operating model and strong international momentum. Vascepa maintained U.S. leadership, while updated guidelines and restructuring supported future growth.